NATURHOUSE HEALTH, S.A. financials
NATURHOUSE HEALTH, S.A.
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
95980007WW7TNTYX8B36 Financial statements
(EUR, as reported — unscaled; 105 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €49.4M | €50.4M |
| Cost of sales | €14.0M | €13.7M |
| Gross profit | €35.5M | €36.7M |
| Other income | €177.0K | €473.0K |
| Employee benefits expense | €9.8M | €9.3M |
| Depreciation & amortisation | €1.9M | €2.3M |
| Operating profit (EBIT) | €13.1M | €16.3M |
| Net finance income / (cost) | -€80.0K | -€699.0K |
| Finance costs | €596.0K | €616.0K |
| Profit before tax | €13.5M | €15.4M |
| Income tax expense | €3.7M | €4.2M |
| Profit for the year | €9.9M | €11.2M |
| — attributable to owners | €9.9M | €11.3M |
| — attributable to NCI | €0 | €46.0K |
| Total comprehensive income | €9.8M | €11.8M |
| Per share | ||
| Basic EPS | €0.16 | €0.19 |
| Diluted EPS | €0.16 | €0.19 |
| Free cash flow / share | €0.18 | €0.34 |
| Cash flow statement | ||
| Net cash from operating activities | €11.6M | €20.9M |
| Net cash from investing activities | €862.0K | -€459.0K |
| Net cash from financing activities | -€16.1M | -€7.7M |
| Dividends paid | €12.0M | €6.0M |
| Repayments of borrowings | €4.1M | €1.7M |
| Balance sheet | ||
| Total assets | €42.6M | €48.8M |
| Non-current assets | €14.4M | €14.5M |
| Property, plant & equipment | €3.3M | €3.7M |
| Current assets | €28.2M | €34.4M |
| Trade & other receivables | €1.7M | €2.3M |
| Cash & equivalents | €20.7M | €24.4M |
| Total equity | €31.7M | €30.6M |
| — attributable to owners | €31.7M | €30.6M |
| Non-controlling interests | €6.0K | €6.0K |
| Non-current liabilities | €4.4M | €5.5M |
| Current liabilities | €6.5M | €12.8M |
| Deferred tax liabilities | €244.0K | €275.0K |
| Derived metrics | ||
| Free cash flow | €11.2M | €20.4M |
| Operating margin | 26.6% | 32.3% |
| Net margin | 20.0% | 22.3% |
| Return on equity | 31.1% | 36.7% |
| Cash conversion ratio | 1.17× | 1.86× |
| Capex coverage | 34.20× | 36.75× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€692.0K | -€84.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | €66.0K | -€111.0K |
| Adjustments For Depreciation and Amortisation Expense | €1.9M | €2.3M |
| Adjustments For Finance Costs | €596.0K | €616.0K |
| Adjustments For Increase Decrease In Trade Account Payable | -€401.0K | €524.0K |
| Adjustments For Interest Income | €542.0K | €43.0K |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€14.0K | €14.0K |
| Adjustments For Provisions | -€788.0K | -€694.0K |
| Adjustments For Reconcile Profit Loss | €1.7M | €2.4M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -€473.0K | €150.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €26.0K | €126.0K |
| Changes In Equity | €9.8M | €11.8M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | -€46.0K |
| Comprehensive Income Attributable To Owners of Parent | €9.8M | €11.8M |
| Current Tax Assets Current | €702.0K | €1.5M |
| Current Tax Liabilities Noncurrent | €524.0K | €2.8M |
| Deferred Tax Assets | €58.0K | €79.0K |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | -€14.0K | €14.0K |
| Dividends Received Classified As Investing Activities | €152.0K | €292.0K |
| Dividends Recognised As Distributions To Owners of Parent | €3.0M | €6.0M |
| Dividends Recognised As Distributions To Owners of Parent Relating To Prior Years | €6.0M | €3.0M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€26.0K | -€517.0K |
| Equity and Liabilities | €42.6M | €48.8M |
| Finance Income | €542.0K | €43.0K |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -€26.0K | -€126.0K |
| Income Taxes Paid Refund Classified As Investing Activities | -€3.1M | €2.8M |
| Increase Decrease In Cash and Cash Equivalents | -€3.7M | €12.3M |
| Increase Decrease In Working Capital | -€751.0K | €107.0K |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | €229.0K | -€6.0M |
| Increase Decrease Through Treasury Share Transactions | €0 | €0 |
| Intangible Assets Other Than Goodwill | €371.0K | €444.0K |
| Interest Paid Classified As Financing Activities | €596.0K | €90.0K |
| Interest Received Classified As Investing Activities | €542.0K | €43.0K |
| Inventories Total | €3.4M | €2.8M |
| Investment Accounted For Using Equity Method | €10.2M | €9.8M |
| Issued Capital | €3.0M | €3.0M |
| Noncurrent Provisions | €930.0K | €1.6M |
| Other Adjustments For Noncash Items | €276.0K | -€222.0K |
| Other Cash Payments From Operating Activities | €988.0K | €0 |
| Other Comprehensive Income | €9.8M | €11.8M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€38.0K | €517.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Current Financial Assets | €1.4M | €3.2M |
| Other Current Financial Liabilities | €1.0M | €4.5M |
| Other Expense By Function | €10.4M | €9.3M |
| Other Gains Losses | -€331.0K | -€10.0K |
| Other Noncurrent Financial Assets | €456.0K | €467.0K |
| Other Noncurrent Financial Liabilities | €3.3M | €3.5M |
| Other Shortterm Provisions | €388.0K | €465.0K |
| Payments of Other Equity Instruments | €0 | €0 |
| Proceeds From Disposal Or Maturity of Availableforsale Financial Assets | €4.1M | €7.7M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €189.0K | €49.0K |
| Proceeds From Sale Or Issue of Treasury Shares | €0 | €0 |
| Profit Loss From Continuing Operations | €9.9M | €11.2M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €338.0K | €570.0K |
| Reserve of Exchange Differences On Translation | -€275.0K | -€237.0K |
| Retained Earnings | €23.1M | €20.6M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €473.0K | -€150.0K |
| Share Premium | €2.1M | €2.1M |
| Trade and Other Current Payables To Related Parties | €2.7M | €2.7M |
| Trade and Other Current Receivables Due From Related Parties | €227.0K | €234.0K |
| Trade and Other Payables | €1.9M | €2.3M |
| Treasury Shares | €142.0K | €142.0K |
Methodology
Every line item above is a fact tagged in NATURHOUSE HEALTH, S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.